Travis M. Figg

Array ( [id] => 19339337 [patent_doc_number] => 12049515 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-30 [patent_title] => Agonistic CD28 antigen binding molecules targeting Her2 [patent_app_type] => utility [patent_app_number] => 17/354409 [patent_app_country] => US [patent_app_date] => 2021-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 32 [patent_no_of_words] => 51880 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 657 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17354409 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18685202 [patent_doc_number] => 11780920 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-10 [patent_title] => Antibodies binding to CD3 and CD19 [patent_app_type] => utility [patent_app_number] => 17/350111 [patent_app_country] => US [patent_app_date] => 2021-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 16 [patent_no_of_words] => 51442 [patent_no_of_claims] => 59 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17350111 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18484981 [patent_doc_number] => 20230212296 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => SYSTEMS AND METHODS FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/928778 [patent_app_country] => US [patent_app_date] => 2021-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19053 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17928778 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18581543 [patent_doc_number] => 20230263795 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => COMBINED PHARMACEUTICAL COMPOSITION OF C-MET KINASE INHIBITOR AND ANTI-PD-L1 ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/999028 [patent_app_country] => US [patent_app_date] => 2021-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14711 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17999028 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17243530 [patent_doc_number] => 20210363273 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-25 [patent_title] => BINDING MOLECULES FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 17/323844 [patent_app_country] => US [patent_app_date] => 2021-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58656 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17323844 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17243530 [patent_doc_number] => 20210363273 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-25 [patent_title] => BINDING MOLECULES FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 17/323844 [patent_app_country] => US [patent_app_date] => 2021-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58656 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17323844 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17243530 [patent_doc_number] => 20210363273 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-25 [patent_title] => BINDING MOLECULES FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 17/323844 [patent_app_country] => US [patent_app_date] => 2021-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58656 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17323844 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17243530 [patent_doc_number] => 20210363273 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-25 [patent_title] => BINDING MOLECULES FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 17/323844 [patent_app_country] => US [patent_app_date] => 2021-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58656 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17323844 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19389420 [patent_doc_number] => 20240279290 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => MULTISPECIFIC PROTEINS [patent_app_type] => utility [patent_app_number] => 17/925144 [patent_app_country] => US [patent_app_date] => 2021-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44813 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17925144 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17548184 [patent_doc_number] => 20220119525 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => HETERODIMERIC ANTIBODIES THAT BIND PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND CD3 [patent_app_type] => utility [patent_app_number] => 17/321325 [patent_app_country] => US [patent_app_date] => 2021-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37951 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17321325 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20264178 [patent_doc_number] => 12435154 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-07 [patent_title] => Bispecific antibodies against CD3 and CD20 [patent_app_type] => utility [patent_app_number] => 17/314946 [patent_app_country] => US [patent_app_date] => 2021-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 25461 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17314946 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17214834 [patent_doc_number] => 20210348171 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => PHARMACOPROTEOMICS PLATFORM IDENTIFYING KINOME FEATURES REGULATING DRUG RESPONSE IN CANCER [patent_app_type] => utility [patent_app_number] => 17/313512 [patent_app_country] => US [patent_app_date] => 2021-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20236 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17313512 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18405822 [patent_doc_number] => 20230167173 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-01 [patent_title] => TREATMENT OF DISEASES WITH CLEVER-1 INHIBITION IN COMBINATION WITH AN INTERLEUKIN INHIBITOR [patent_app_type] => utility [patent_app_number] => 17/919923 [patent_app_country] => US [patent_app_date] => 2021-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8613 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 138 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17919923 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18322039 [patent_doc_number] => 20230120167 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => VARIANTS OF SAC7D AND THEIR USE IN CANCER THERAPY [patent_app_type] => utility [patent_app_number] => 17/906000 [patent_app_country] => US [patent_app_date] => 2021-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16348 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17906000 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18320830 [patent_doc_number] => 20230118958 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => ANTI-TUMOR COMPOSITION [patent_app_type] => utility [patent_app_number] => 17/904953 [patent_app_country] => US [patent_app_date] => 2021-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4816 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17904953 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18268315 [patent_doc_number] => 20230089557 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => METHODS OF TREATING DLBCL USING BTK INHIBITORS AND COMBINATIONS THEREOF [patent_app_type] => utility [patent_app_number] => 17/802111 [patent_app_country] => US [patent_app_date] => 2021-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6118 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17802111 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18391420 [patent_doc_number] => 20230159638 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-25 [patent_title] => EX VIVO GAMMA DELTA T CELL POPULATIONS [patent_app_type] => utility [patent_app_number] => 17/904890 [patent_app_country] => US [patent_app_date] => 2021-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47383 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17904890 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17037029 [patent_doc_number] => 20210253987 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => METHOD AND DEVICE FOR EARLY CANCER SCREENING [patent_app_type] => utility [patent_app_number] => 17/180492 [patent_app_country] => US [patent_app_date] => 2021-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59364 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17180492 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18483686 [patent_doc_number] => 20230210988 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => MEANS AND METHOD FOR MODULATING IMMUNE CELL ENGAGING EFFECTS [patent_app_type] => utility [patent_app_number] => 17/759728 [patent_app_country] => US [patent_app_date] => 2021-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25761 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17759728 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18299532 [patent_doc_number] => 20230109218 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-06 [patent_title] => Conditionally Active Anti-Her2 Antibodies, Antibody Fragments Their Immunoconjugates And Uses Thereof [patent_app_type] => utility [patent_app_number] => 17/759195 [patent_app_country] => US [patent_app_date] => 2021-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 71379 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17759195 [rel_patent_id] =>[rel_patent_doc_number] =>)